Earnings Call · Q2 FY2025·2025-08-08

Q2 25EPS -13.79%·Rev n/aQ1 25EPS -50.00%·Rev n/aQ4 24EPS +2.84%·Rev n/aQ3 24EPS +6.67%·Rev n/a⚠ consensus missing

IOVANCE BIOTHERAPEUTICS, INC. IOVA

Sara Pellegrino — Senior Vice President of Investor Relations & Corporate Communications

Frederick G. Vogt — Interim Chief Executive Officer and President

Daniel G. Kirby — Senior Executive, likely Chief Commercial Officer or similar

Igor P. Bilinsky — Head of Manufacturing or similar executive role in manufacturing

Friedrich Graf Finckenstein — Senior Executive or Head of Clinical Development

−20.1%1d on move date−20.9% vs SPY3d−15.5%5d−7.2%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more IOVA calls or request research access.

More IOVA calls Browse calls Request research access